A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer
Authors
Keywords
Irinotecan, UCN-01, Chk1, Metastatic triple negative breast cancer, <em class=EmphasisTypeItalic >TP53</em>, p53
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 137, Issue 2, Pages 483-492
Publisher
Springer Nature
Online
2012-12-14
DOI
10.1007/s10549-012-2378-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting triple-negative breast cancer: optimising therapeutic outcomes
- (2012) K. Gelmon et al. ANNALS OF ONCOLOGY
- Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models
- (2012) Cynthia X. Ma et al. JOURNAL OF CLINICAL INVESTIGATION
- Dissecting the Heterogeneity of Triple-Negative Breast Cancer
- (2012) Otto Metzger-Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Molecular heterogeneity of triple-negative breast cancer and its clinical implications
- (2011) Sheeba Irshad et al. CURRENT OPINION IN ONCOLOGY
- Targeting the S and G2 checkpoint to treat cancer
- (2011) Tao Chen et al. DRUG DISCOVERY TODAY
- p53 Status Identifies Two Subgroups of Triple-negative Breast Cancers with Distinct Biological Features
- (2011) E. Biganzoli et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies
- (2010) Paula M. Fracasso et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
- (2010) Cynthia X. Ma et al. TRENDS IN MOLECULAR MEDICINE
- DDB1 Targets Chk1 to the Cul4 E3 Ligase Complex in Normal Cycling Cells and in Cells Experiencing Replication Stress
- (2009) V. Leung-Pineda et al. CANCER RESEARCH
- Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
- (2009) Farrah Kassam et al. Clinical Breast Cancer
- Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor-Negative Breast Cancer
- (2009) C. Speers et al. CLINICAL CANCER RESEARCH
- p53 as a Specific Prognostic Factor in Triple-negative Breast Cancer
- (2009) B. J. Chae et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- The F Box Protein Fbx6 Regulates Chk1 Stability and Cellular Sensitivity to Replication Stress
- (2009) You-Wei Zhang et al. MOLECULAR CELL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started